ARTICLE | Clinical News
Cytovaxine: CBX began a double-blind, dose-escalation Canadian Phase I trial in 35 healthy volunteers. Shire Pharmaceuticals Group plc (LSE:SHP, SHPGY, Basingst
April 8, 2002 7:00 AM UTC
Cytovax Biotechnologies Inc. (TSE:CBX), Edmonton, Alberta Product: Cytovaxine Business: Infectious diseases Therapeutic category: Vaccine Target: Immune cells Description: Peptide vaccine derived from...